Based on the idea that combining treatments with complementary mechanisms of action might induce and maintain remission of both disease components,6 7 we investigated the efficacy and safety of a regimen based on sequential rituximab and mepolizumab for the control of EGPA.
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study
Lopalco G.;Iannone F.;
2022-01-01
Abstract
Based on the idea that combining treatments with complementary mechanisms of action might induce and maintain remission of both disease components,6 7 we investigated the efficacy and safety of a regimen based on sequential rituximab and mepolizumab for the control of EGPA.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis.pdf
non disponibili
Descrizione: articolo principale
Tipologia:
Documento in Versione Editoriale
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
499.29 kB
Formato
Adobe PDF
|
499.29 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
